SOCS2 and neoplasm: Our data showing the reduced expression of the SOCS2 L163P and C167F SOCS-box and the R73E SH2-domain mutants, which are defective in Elongin C interaction lend support to these hypotheses and is in line with previous data from studies with VHL tumour suppressor SOCS-box point mutations [29].